Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5718 in active rheumatoid arthritis
NCT05165771Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of edecesertib in rheumatoid arthritis (RA), sponsored by Gilead Sciences. Planned start Jul 2022; status: withdrawn.
02
Drugs
edecesertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05165771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165771.